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Hepatitis C virus (HCV) infection is a blood-borne infection and its prevalence used to be elevated in hemodialysis (HD) patients.
Its main mode of contamination relies on nosocomial transmission. HCV infection is frequently associated in HD patients with
normal liver enzymes whereas liver histology can display some degree of HCV-related lesions. The assessment of HCV-related
lesions, even in HD dialysis patients, can be done via noninvasive tests. After kidney transplantation, HCV-related lesions can
worsen; however, in this setting antiviral treatment harbors the risk of acute rejection. Therefore, it is recommended to implement
antiviral treatment while the patient is receiving dialysis therapy. In this setting, the rate of viral clearance is usually high. In case
of sustained virological response, no relapse occurs after kidney transplantation, despite heavy immunosuppression.
1.Introduction
The most important forms of liver disease in dialysis
patients are viral hepatitis B (HBV) and C (HCV). The
vast majority of literature on dialysis for hepatitis refers to
hemodialysis (HD). Individuals receiving peritoneal dialysis
(PD) are at less risk of acquiring blood-borne infections
for several reasons, including an absence of extracorporeal
blood manipulation, a lack of intravascular access, as well as
a lower requirement for blood transfusions. Also, PD takes
place in the patient’s home, where there is no exposure to
other patients.
An accurate assessment of the natural history of HCV
in dialysis patients is not easy to obtain. HCV infection
in dialysis patients is often asymptomatic with an apparent
indolent course. HCV infection extends over decades rather
than years whereas chronic kidney-disease (CKD) patients
generally have higher morbidity and mortality rates than
those of the general population, due to age and comorbidity
conditions [1]. This makes the long-term consequences of
HCV diﬃcult to establish. Additional factors also modify
the course of liver disease, including HBV/HCV coinfection,
coinfection with human immunodeﬁciency virus, or alcohol
abuse.
Because of the wide use of antiviral drugs and because
posttransfusional hepatitis no longer occurs, future natural-
history studies on chronic HCV will become less possible
[2]. Accurate evaluation of HCV infection in the CKD
population is further complicated by the observation that
aminotransferase values are typically lower in dialysis than
nonuremic populations [3]. However, dialysis patients that
do show detectable HCV RNA have aminotransferase levels2 Hepatitis Research and Treatment
greater than those who do not, although values are typically
within the “normal” range [4, 5]. Therefore, if one wants
to assess the impact of chronic HCV infection in CKD
patients, a liver biopsy is usually performed [2]. However,
a liver biopsy may be replaced by noninvasive tests, such
a saF i b r o T e s to raF i b r o S c a n[ 6, 7], and these tests are
of particular interest when there is a possibility of kidney
transplantation to treat CKD.
2. HCV-RelatedOutcomes in
the CKD Population
A recent meta-analysis on the impact of HCV on mortality
in 11,589 maintenance-dialysis patients, from seven observa-
tional studies, concluded that the estimated adjusted relative
risk (aRR: all cause mortality) was 1.34 (1.13−1.59; P<. 01)
[8]. The cause of death as hepatocellular carcinoma and the
incidence of liver cirrhosis, were signiﬁcantly more frequent
among anti-HCV-positive than anti-HCV-negative dialysis
patients in all seven studies. The unadjusted summary
estimate for liver-related mortality was 5.89 (1.93−17.99; P<
.001) according to a random-eﬀects model [8].
Recently, Kalantar-Zadeh et al. [9] evaluated a database
of 13,664 chronic HD patients in the United States who had
undergone HCV serology. They observed that the mortality-
hazard ratio was strongly associated with HCV infection:
that is, it was 1.25 (1.12−1.39; P<. 001). Thus, when HCV-
positive CKD patients undergo kidney transplantation, it is
possible that the natural course of chronic HCV infection is
altered by the use of chronic immunosuppression. Indeed,
two studies have shown that survival was signiﬁcantly
improved in HCV-positive patients who had beneﬁted from
a kidney transplant compared to those who remained on a
kidney waiting list [10, 11].
Afterkidneytransplantation,withintheﬁrst5yearspost-
transplant, patient survival is similar in both HCV-positive
and HCV-negative patients [12–14]. However, when 10-year
survival rates are examined, HCV then appears to be a
detrimental eﬀect [12–14]. A meta-analysis of observational
studies identiﬁed eight clinical trials (6,365 unique patients)
in which the presence of anti-HCV antibodies in the serum
was an independent and signiﬁcant risk factor for death and
graft failure after kidney transplantation. The estimates for
relative risk (RR) were 1.79 (1.57−2.03) and 1.56 (1.35−1.80),
respectively [15].
The adverse impact of HCV on survival after kidney
transplantation has been linked to liver dysfunction. Fur-
thermore, a positive anti-HCV serology in kidney-transplant
patients has been implicated in the development of de
novo glomerulopathy [19], an increased incidence of serious
infections [20], and new-onset diabetes mellitus [21]. In
addition, in kidney-transplant patients, the use of alpha-
interferon (αIFN) to treat HCV infection has been associated
with (i) a poor response to antiviral therapy and (ii) the
occurrence of a high rate of acute rejection, that is, up to
50% in some series [22, 23]. The latter were mainly humoral
(sub)acute rejections [24]. Conversely, in kidney-transplant
patients, the use of pegylated alpha-interferon (pegαIFN),
although more limited, has been rarely associated with acute
allograft rejection [25]. Because of the above concerns, it
seems reasonable to treat HCV infection while the patient
is on dialysis, that is, before they are placed on a kidney-
transplant waiting list.
3. HCV Treatment in the General Population
At the moment, the best treatment for chronic HCV
infection in patients with normal renal function relies on
the combined use of pegαIFN and ribavirin (RBV). Thus,
Hartwell and Shepherd recently performed a meta-analysis
that included ten randomized, controlled trials (RCTs) in
which treatment was based on pegαIFN/RBV or αIFN/RBV
[26]. pegαIFN/RBV therapy resulted in signiﬁcantly higher
sustained virological response (SVR) rates than treatment
with the combined αIFN/RBV therapy. Treatment for 48
w e e k sw i t hp e g αIFN/RBV was signiﬁcantly more eﬀective
than the same treatment for 24 weeks. Signiﬁcantly higher
SVR rates were seen with combined αIFN/RBV compared
to either an αIFN monotherapy or to no treatment. In this
meta-analysis (four αIFN trials), the relative risk of not
experiencing an SVR was 0.59 (95% CI, 0.51−0.69) and
was highly statistically signiﬁcant (P<. 00001). SVRs were
higher for patients with genotype non-1 compared with
genotype 1 for both pegαIFN/RBV and IFN/RBV treatments
[26].
4. HCVTreatment in the CKD Population
The AASLD (American Association for the Study of Liver
Diseases) has published guidelines for the CKD population
stating that “when HCV infection is identiﬁed in persons
with CKD, interferon-based antiviral treatment must be
considered, but the regimen will vary depending of the
kidney disease...The decision to treat must take into account
the competing severities of the CKD and the chronic liver
disease, the risks of the treatment itself, ..., and whether
there are comorbid conditions that may aﬀect morbidity and
mortality, such as cardiovascular disease.” [27].
The kidneys play a major role in the catabolism and
ﬁltration of both interferon and ribavirin; thus, their
clearances may be aﬀected in subjects with CKD [28,
29]. The clearance of pegylated interferon is aﬀected in
those with CKD, although hemodialysis does not aﬀect its
clearance [30]. Hence, the AASLD guidelines recommend
subcutaneousweeklydosesof1μg/kgofpeginterferonalpha-
2b and of 135μg of peginterferon alpha-2a [27] to patients
with stage 3−5 CKD. Because ribavirin is eliminated by the
kidney, and if overdosed might result in dramatic anemia
[31], ribavirin therapy is contraindicated when creatinine
clearance is <50mL/min. Hence, most data regarding HCV
treatment in the CKD population deal with the use of either
standard α-interferon or α-pegylated interferon.
5 .T r eatm e n to fCh r o n icHCVI n f ec tio nin
CKD Patients
With regards to end-stage kidney-disease (ESKD) patients
who are chronically treated by dialysis, Casanovas-TaltavullHepatitis Research and Treatment 3
Table 1: Treatment with alpha-interferon or pegylated-alpha interferon in dialysis HCV positive patients: results from 3 meta-analyses.
Meta-analysis 1
(Fabrizi et al. [16])
Meta-analysis 2
(Gordon et al. [17])
Meta-analysis 3
(Alavian and Tabatabaei; [18])
Number of studies 28 25 33
Number of patients 645 459 770
Overall SVR (standard
IFN/Peg-INF) % 39/41 41/37 39.1/39.3
Genotype 1(%) 33 Not reported Not reported
Treatment discontinuation
(standard IFN/Peg-IFN/Placebo) % 19/27/ not reported 26/28/22 22.6/29.7/not reported
SVR: sustained virological response; IFN: alpha-interferon; Peg-IFN: pegylated alpha-interferon.
et al. reviewed two meta-analyses (Meta-1 and Meta-2) pub-
lished in 2008 (Table 1). From these, they analyzed the SVRs,
any adverse eﬀects, and the reasons for discontinuing αIFN
treatment in dialysis patients [32]. The Meta-1 study ana-
lyzed results obtained from 645 patients; the Meta-2 study
used data from 459 patients (19 studies were duplicated).
Overall, the SVR was 40%; SVR in genotype 1 was 33%,
with pegylated interferon providing few additional beneﬁts
over conventional alpha-interferon. Adverse events, such
as typical ﬂu-like syndrome occurred in 41% of patients,
requiring withdrawal of antiviral treatment in 11% of them.
A high rate of anemia was also documented, although
the use of recombinant erythropoietin, intravenous iron
administration, or transfusions was not generally reported.
A typical ﬂu-like syndrome occurred in 41% of patients,
which required withdrawal of antiviral treatment in 11%.
Severeadverseeventsweredividedintothefollowinggroups:
hormonal (thyroid), bone pain, cytopenia, gastrointestinal,
immunological (prior graft rejection), central nervous sys-
tem, cardiovascular, and infectious problems. The reviewers
of these meta-analyses pointed out any bias in the selection
criteria of candidates for treatment, limitations related to the
n u m b e ra n dt y p eo fa d v e r s ee ﬀects (as well as their clinical
evaluation), and discrepancies in cases of discontinuation of
treatment or loss to follow-up.
With regards to Meta-1, the primary outcome was a
SVR (as a measure of eﬃcacy); the secondary outcome
was the drop-out rate (as a measure of tolerability) [16].
Theyidentiﬁed13prospectivestudies,whichwerecontrolled
clinical trials that included 539 unique patients, of whom
10 (76.9%) patients were receiving maintenance dialysis.
Pooling of these studies’ results showed a signiﬁcant increase
in viral response of patients treated with antiviral therapy
compared to patients who did not receive any therapy
(controls). The pooled odds ratio (OR) of failure to obtain a
SVR was 0.081 (95% conﬁdence intervals (CI), 0.029−0.230),
P = .0001. The pooled OR of drop-out rate was signiﬁcantly
increasedintreatedversuscontrolpatients,OR =0.389(95%
CI, 0.155−0.957), P = .04. The studies were heterogeneous
with regard to viral response and drop-out rate. In the subset
of clinical trials (n = 6) involving only dialysis patients
receiving α-IFN monotherapy for chronic HCV, there was a
signiﬁcant diﬀerence in the risk of failure to obtain a SVR
(study versus control patients), OR = 0.054 (95% CI, 0.019;
0.150),P = .0001.Nodiﬀerenceinthedrop-outratebetween
study and control patients was shown (OR = 0.920 (95% CI,
0.367; 2.311), NS). Meta-1 showed that viral response was
greater in patients with chronic kidney disease who received
antiviraltherapythanincontrols.Nodiﬀerencesinthedrop-
out rates between study and control patients occurred in the
subgroup of dialysis patients on α-IFN monotherapy [16].
With regards to Meta-2, the authors took into account
those chronic dialysis patients with chronic HCV infection
who were either treated with αI F No rp e g αIFN, with
or without ribavirin [17]. They searched on MEDLINE
for indexed studies since 1966, and only selected studies
with a sample size greater than 10. They looked for the
following parameters: SVR at 6 months after treatment,
rate of treatment discontinuation caused by adverse events,
and factors associated with these outcomes. They analyzed
20 studies that contained 459 αIFN-treated patients, three
studies that contained 38 pegαIFN-treated patients, and two
studies that contained 49 pegαIFN and ribavirin-treated
patients. The overall SVR rate was 41% (95% conﬁdence
interval [CI], 33 to 49) for αIFN and 37% (95% CI, 9 to
77) for pegαIFN. Treatment-discontinuation rates were 26%
(95% CI, 20 to 34) for αIFN and 28% (95% CI, 12 to 53)
for pegαIFN. SVR was higher, with 3 million units (MU)
or higher of αIFN at three times weekly, with lower mean
amounts of HCV RNA, lower rates of cirrhosis, a HCV
genotype 1, or elevated transaminase, though these ﬁndings
were not statistically signiﬁcant.
Treatment-discontinuation rates were greater in studies
using larger doses. Hence, side-eﬀects from alpha-interferon
were numerous, particularly in the ESKD population. The
main side eﬀects were fatigue/weakness and loss of appetite,
which may lead to weight loss and, thus, ﬂuid overload if
dry weight is not adapted accordingly. Many patients also
developed anemia, which often requires commencement or
increased treatment with erythropoietin-stimulating agents;
in addition, seizures can occur if there is ﬂuid overload
and hypertension. The limitations of these meta-analyses
were publication bias, there were few randomized controlled
trials, and there were limitations in generalizability of all
hemodialysis patients. In conclusion, alpha-IFN treatment
of hemodialysis patients resulted in an SVR rate of 41%.
Thus, a higher weekly dose of αIFN, a lower mean level of
pretreatment HCV RNA, a lower rate of cirrhosis, an HCV
genotype diﬀerent from 1, and/or decreased transaminase
levels may all be associated with greater SVR rates [17].4 Hepatitis Research and Treatment
A more recent meta-analysis has been published on
a group of 770 hemodialysis patients with chronic HCV
infection (Table 1), in which the authors evaluated factors
that were associated to SVR after α-pegylated or standard α-
IFNmonotherapy.Twenty-onestudiesonα-IFN-alfa2aorα-
IFN-alfa2b (491 patients) and 12 on pegylated-IFN-alfa2a or
PEG-IFN-alfa2b (279 patients) were evaluated. The pooled
SVRs for standard and pegylated α-IFN monotherapy in
random-eﬀectmodelswere39.1%(95%CI,32.1to46.1)and
39.3% (95% CI, 26.5 to 52.1), respectively. Pooled dropout
rates were 22.6% (95% CI, 10.4 to 34.8) and 29.7% (95%
CI, 21.7 to 37.7), respectively. Female gender, HCV-RNA
copiespermL,HCVgenotype,alaninetransaminasepattern,
duration of infection, stage of liver ﬁbrosis, and treatment
duration were not associated with SVR. Only an age less than
40 years was signiﬁcantly associated with SVR (odds ratio,
2.17; 95% CI, 1.03 to 4.50) [18].
There are only few limited reports that describe the
combined use of (peg)alpha-interferon and ribavirin in
dialysis patients. With regard to this combined therapy,
the AASLD guidelines state that “Ribavirin can be used in
combination with interferon with a markedly reduced daily
dose with careful monitoring for anemia and other adverse
eﬀects.” [27]. The largest series published so far on the
combined use of peginterferon alpha-2a plus ribavirin in
hemodialysis patients obtained a SVR rate of 97% (34/35) in
the treated patients (peginterferon alpha-2a plus ribavirin)
versus 0% (0/35) in untreated controls [33]. These ﬁndings
have not been conﬁrmed in further reports where the SVR
rate ranges between 7% and 71% [1].
6 .T r eatm e n to fA c u t eHCVI n f ec tio nin
CKD Patients
In the general population, with regard to the treatment
of acute HCV infection, the AASLD guidelines state that
“Treatment can be delayed for 8 to 12 weeks after acute onset
of hepatitis to allow spontaneous resolution; ...Although
excellent results were achieved using standard interferon
monotherapy, it is appropriate to consider the use of
peginterferon...Until more information becomes available,
no deﬁnitive recommendation can be made about the
optimal duration needed for treatment of acute hepatitis C;
however, it is reasonable to treat for at least 12 weeks and 24
weeks may be considered.” [27].
In dialysis patients, Liu et al. have very recently published
their experience regarding the treatment of acute HCV
infection. They included 35 dialysis patients that had no
spontaneous clearance of HCV at 16 weeks after acute
HCV infection. They were thus then given a course of
peginterferon alpha 2a at 135μgw e e k l yf o r2 4w e e k s[ 34].
They compared the results with those from a historical
series of 36 hemodialysis patients who had acute hepatitis
C, but had not received treatment. The rate of SVR in their
treatment group was signiﬁcantly higher than the rate of
spontaneous HCV clearance in the control historical series
group (88.6% versus 16.7%). All but one patient had a rapid
virologic response (undetectable HCV RNA levels at 4 weeks
of therapy), and all patients who received more than 12
weeks of therapy had early and end-of-treatment virologic
responses. All patients who had clearance of HCV by 16
weeks had undetectable HCV RNA levels during and at the
end of follow-up. Liu et al. conclude that “Pegylated IFN
alfa-2a monotherapy is safe and eﬃcacious for hemodialysis
patients with acute hepatitis C. It is suggested that patients
without spontaneous clearance of HCV by week 16 should
receive this therapy.” [34].
In addition, dialysis patients who were cleared of the
HCV virus after antiviral therapy, and received kidney trans-
plantation, did not present with HCV reactivation, despite
heavy immunosuppression [35]. Hence, 16 HCV seropos-
itive/HCV RNA-positive hemodialysis patients who were
treated with IFN-alpha (9MU/wk during 6 or 12 months)
underwent kidney transplantation 38 months (range: 2 to
57) after alpha-IFN therapy. At kidney transplantation, HCV
viremia was negative in all patients. Immunosuppression
relied on anticalcineurin agents with or without steroids
and/or antimetabolites; in addition, 12 of them received
induction therapy with antithymocyte globulins; at the last
follow-up after kidney transplantation, that is, 22.5 months
(range, 2 to 88), HCV viremia remained negative in all
patients [35]. Recently, we have assessed the persistence of
HCV infection in 26 HCV seropositive kidney-transplant
patients currently receiving immunosuppressants, and who
wereformerlyinfectedwithHCV,thatis,theyhadeliminated
HCV either spontaneously or after interferon-α therapy
while on hemodialysis [36]. No biochemical or virolog-
ical relapse was seen during the median posttransplant
follow-up of 10.5 years (range: 2−16) in those patients
who received immunosuppressive therapy that included
calcineurininhibitors(100%),and/orsteroids(62%),and/or
antimetabolites (94%). At the last follow-up, all had unde-
tectable HCV RNA according to the conventional tests that
were repeated, on average, ﬁve times (range, 1−15). We also
looked for residual HCV RNA in their plasma and peripheral
blood-mononuclear cells (PBMCs) (stimulated or not in
culture) with an ultrasensitive RT-PCR assay, followed by
Southern blotting for PBMCs: no HCV genomic RNA was
detected in the plasma samples or in the unstimulated and
stimulated PBMCs. Thus, an absence of a relapse of HCV
in formerly HCV-infected immunocompromised patients
suggests complete eradication of HCV after its elimination
while on dialysis [36]. These ﬁndings highlight the fact
that HCV-positive dialysis patients who have a SVR after
completion of alpha-(peg)interferon therapy are really cured
of HCV.
We conclude that, because it is not always safe to treat
HCV infection after kidney transplantation, antiviral treat-
ment should be implemented before transplantation, that is,
while the patient is ondialysis therapy. The evidence suggests
that treatment might be based on alpha interferon (standard
or pegylated), this results in a high rate of sustained viral
clearance.Incaseswherethereisnovirologicalresponse,one
could add very low doses of ribavirin therapy to the alpha-
interferon in order to maximise the virological response.
However, one needs to be mindful of the risk of hemolytic
anemia. Finally, dialysis HCV seropositive patients who have
a sustained virological response after antiviral therapy doHepatitis Research and Treatment 5
not relapse after kidney transplantation despite powerful
immunosuppressive therapy.
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